In the vast majority of cases of Parkinson’s disease, or “shaking palsy,” physicians cannot be sure what originally caused the nerve damage that results in the patient’s tremor, muscle rigidity, ...
Philadelphia (April 1, 2022) – Researchers have engineered probiotic bacteria that can synthesize the dopamine precursor L-DOPA, a powerful mainstay treatment for Parkinson’s disease. Preclinical ...
A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million ...
The U.S. Food and Drug Administration has given approval for the drug Stalevo-a cocktail of levodopa (L-dopa), carbidopa, and entacapone-to be marketed in the United States for the treatment of ...
Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ...
From the Medical Research Center, Brookhaven National Laboratory, Upton, L.I., and the Faculty of Medicine, Catholic University, Santiago, Chile (address reprint requests to Dr. Cotzias at the Medical ...
A drug used to treat Parkinson's disease could also help people with phobias or post-traumatic stress disorder (PTSD), scientists report. They are currently exploring the effects of psychotherapy to ...
Study suggests L-DOPA therapy for Angelman syndrome may have both benefits and unanticipated effects
CHAPEL HILL, N.C. – Last year a clinical trial of L-DOPA -- a mainstay of Parkinson's disease therapy -- was launched for Angelman syndrome, a rare intellectual disorder that shares similar motor ...
Researchers have discovered one of the first concrete examples of how the microbiome can interfere with a drug's intended path through the body. Focusing on levodopa (L-dopa), the primary treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results